Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial
Purpose The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was inve...
Gespeichert in:
| Veröffentlicht in: | Archives of gynecology and obstetrics 2021-02, Vol.303 (2), p.501-511 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 511 |
|---|---|
| container_issue | 2 |
| container_start_page | 501 |
| container_title | Archives of gynecology and obstetrics |
| container_volume | 303 |
| creator | Major, Attila Louis Dvořák, Vladimír Schwarzová, Jana Skřivánek, Aleš Malík, Tomáš Pluta, Marek Mayboroda, Ivanna Grandjean, Etienne Marc |
| description | Purpose
The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was investigated.
Methods
216 women aged 25–60 years were randomized to either receive an intravaginal daily dose of SAM gel for three 28-day periods, or be followed-up without intervention. The primary endpoint was efficacy, defined as a combined histological and cytological regression. At baseline and after 3 months participants had: a guided biopsy including p16 immunohistochemical (IHC) staining, only if a lesion was visible at colposcopy; a cervical smear for cytology, high-risk human papillomavirus (hr-HPV) and a p16/Ki-67 test. At 6 months a further cytology and p16/Ki-67 test was performed.
Results
Regression of CIN lesions was observed in 78 out of 108 patients (72.2%) in the SAM gel arm and in 27 out of 108 patients (25.0%) in the control arm. Similarly, the change in the p16/Ki-67 cytological test status was significantly in favor of the treatment arm. The prevalence of hr-HPV decreased significantly (
p
|
| doi_str_mv | 10.1007/s00404-020-05816-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7858556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2485942092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-88abbbfd14939521b04dc453ca47a8e857d017274ee4f0e14018d4183fc91daf3</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EoqHwAiyQJTYsanrt8Yw9LJBQ1NKKClgAW8vjn8RlMg72JCJ9DV4YT1LKz4KVr-_5fOzrg9BTCi8pgDjNABw4AQYEakkbIu-hGeUVIyAovY9m0E41NOIIPcr5GoAyKZuH6KiqGG25ZDP048z7YLTZYT1YnLV34w5HX3ZY2xxT54ZxL-lhDCR-D1aPYevwVi_CoHu8cD2OA55fvqd7jJ1M22VYLEkK-Su--PjlZC-U7po2p-8CacQrrHEqzbgKN85iE4cxxb4v5ZiC7h-jB1732T25XY_R5_OzT_MLcvXh7eX8zRUxXPCRSKm7rvOW8rZqa0Y74NbwujKaCy2drIUFKpjgznEPjnKg0nIqK29aarWvjtHrg-96062cNWXUpHu1TmGl005FHdTfyhCWahG3Ssha1nVTDF7cGqT4bePyqFYhG9f3enBxkxXjTUVLRkwW9Pk_6HXcpPKDEyXrljNoWaHYgTIp5pycv3sMBTVlrg6Zq5K52meuJutnf45xd-RXyAWoDkAu0rBw6ffd_7H9CaMLtiU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2485942092</pqid></control><display><type>article</type><title>Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Major, Attila Louis ; Dvořák, Vladimír ; Schwarzová, Jana ; Skřivánek, Aleš ; Malík, Tomáš ; Pluta, Marek ; Mayboroda, Ivanna ; Grandjean, Etienne Marc</creator><creatorcontrib>Major, Attila Louis ; Dvořák, Vladimír ; Schwarzová, Jana ; Skřivánek, Aleš ; Malík, Tomáš ; Pluta, Marek ; Mayboroda, Ivanna ; Grandjean, Etienne Marc</creatorcontrib><description>Purpose
The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was investigated.
Methods
216 women aged 25–60 years were randomized to either receive an intravaginal daily dose of SAM gel for three 28-day periods, or be followed-up without intervention. The primary endpoint was efficacy, defined as a combined histological and cytological regression. At baseline and after 3 months participants had: a guided biopsy including p16 immunohistochemical (IHC) staining, only if a lesion was visible at colposcopy; a cervical smear for cytology, high-risk human papillomavirus (hr-HPV) and a p16/Ki-67 test. At 6 months a further cytology and p16/Ki-67 test was performed.
Results
Regression of CIN lesions was observed in 78 out of 108 patients (72.2%) in the SAM gel arm and in 27 out of 108 patients (25.0%) in the control arm. Similarly, the change in the p16/Ki-67 cytological test status was significantly in favor of the treatment arm. The prevalence of hr-HPV decreased significantly (
p
< 0.001) in the treatment arm, from 87.0% to 39.8%, while it slightly increased in the control arm, from 78.7% to 83.3%. At 6 months the cytological regression in the treatment group and the highly significant effect on p16/Ki-67 was still present.
Conclusion
SAM vaginal gel enhances the regression of cervical lesions and clears hr-HPV and p16/Ki-67 in smears significantly, thus offering an active non-destructive management to prevent cervical cancer.
Trial registration number
ISRCTN11009040, date of registration: 10/12/2019;
https://doi.org/10.1186/ISRCTN11009040
; retrospectively registered.</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-020-05816-8</identifier><identifier>PMID: 33219482</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Administration, Intravaginal ; Adult ; Antioxidants - administration & dosage ; Biomarkers, Tumor - analysis ; Cancer therapies ; Cellular biology ; Cervical cancer ; Cervical Intraepithelial Neoplasia - pathology ; Cervical Intraepithelial Neoplasia - therapy ; Citric Acid - administration & dosage ; Clinical trials ; Colposcopy ; Cyclin-Dependent Kinase Inhibitor p16 - drug effects ; Cytodiagnosis ; Endocrinology ; Female ; General Gynecology ; Genes, p16 ; Gynecology ; Human Genetics ; Human papillomavirus ; Humans ; Ki-67 Antigen - drug effects ; Medical equipment ; Medical screening ; Medicine ; Medicine & Public Health ; Middle Aged ; Obstetrics/Perinatology/Midwifery ; Oxidative stress ; Papillomavirus Infections - therapy ; Papillomavirus Infections - virology ; Pregnancy ; Silicon Dioxide - administration & dosage ; Sodium Selenite - administration & dosage ; Treatment Outcome ; Uterine Cervical Neoplasms - prevention & control ; Vagina ; Vaginal Creams, Foams, and Jellies ; Vaginal Smears ; Womens health]]></subject><ispartof>Archives of gynecology and obstetrics, 2021-02, Vol.303 (2), p.501-511</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-88abbbfd14939521b04dc453ca47a8e857d017274ee4f0e14018d4183fc91daf3</citedby><cites>FETCH-LOGICAL-c474t-88abbbfd14939521b04dc453ca47a8e857d017274ee4f0e14018d4183fc91daf3</cites><orcidid>0000-0002-1459-2727</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-020-05816-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-020-05816-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33219482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Major, Attila Louis</creatorcontrib><creatorcontrib>Dvořák, Vladimír</creatorcontrib><creatorcontrib>Schwarzová, Jana</creatorcontrib><creatorcontrib>Skřivánek, Aleš</creatorcontrib><creatorcontrib>Malík, Tomáš</creatorcontrib><creatorcontrib>Pluta, Marek</creatorcontrib><creatorcontrib>Mayboroda, Ivanna</creatorcontrib><creatorcontrib>Grandjean, Etienne Marc</creatorcontrib><title>Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose
The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was investigated.
Methods
216 women aged 25–60 years were randomized to either receive an intravaginal daily dose of SAM gel for three 28-day periods, or be followed-up without intervention. The primary endpoint was efficacy, defined as a combined histological and cytological regression. At baseline and after 3 months participants had: a guided biopsy including p16 immunohistochemical (IHC) staining, only if a lesion was visible at colposcopy; a cervical smear for cytology, high-risk human papillomavirus (hr-HPV) and a p16/Ki-67 test. At 6 months a further cytology and p16/Ki-67 test was performed.
Results
Regression of CIN lesions was observed in 78 out of 108 patients (72.2%) in the SAM gel arm and in 27 out of 108 patients (25.0%) in the control arm. Similarly, the change in the p16/Ki-67 cytological test status was significantly in favor of the treatment arm. The prevalence of hr-HPV decreased significantly (
p
< 0.001) in the treatment arm, from 87.0% to 39.8%, while it slightly increased in the control arm, from 78.7% to 83.3%. At 6 months the cytological regression in the treatment group and the highly significant effect on p16/Ki-67 was still present.
Conclusion
SAM vaginal gel enhances the regression of cervical lesions and clears hr-HPV and p16/Ki-67 in smears significantly, thus offering an active non-destructive management to prevent cervical cancer.
Trial registration number
ISRCTN11009040, date of registration: 10/12/2019;
https://doi.org/10.1186/ISRCTN11009040
; retrospectively registered.</description><subject>Administration, Intravaginal</subject><subject>Adult</subject><subject>Antioxidants - administration & dosage</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer therapies</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Cervical Intraepithelial Neoplasia - pathology</subject><subject>Cervical Intraepithelial Neoplasia - therapy</subject><subject>Citric Acid - administration & dosage</subject><subject>Clinical trials</subject><subject>Colposcopy</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - drug effects</subject><subject>Cytodiagnosis</subject><subject>Endocrinology</subject><subject>Female</subject><subject>General Gynecology</subject><subject>Genes, p16</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Ki-67 Antigen - drug effects</subject><subject>Medical equipment</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Oxidative stress</subject><subject>Papillomavirus Infections - therapy</subject><subject>Papillomavirus Infections - virology</subject><subject>Pregnancy</subject><subject>Silicon Dioxide - administration & dosage</subject><subject>Sodium Selenite - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Uterine Cervical Neoplasms - prevention & control</subject><subject>Vagina</subject><subject>Vaginal Creams, Foams, and Jellies</subject><subject>Vaginal Smears</subject><subject>Womens health</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1uEzEUhS0EoqHwAiyQJTYsanrt8Yw9LJBQ1NKKClgAW8vjn8RlMg72JCJ9DV4YT1LKz4KVr-_5fOzrg9BTCi8pgDjNABw4AQYEakkbIu-hGeUVIyAovY9m0E41NOIIPcr5GoAyKZuH6KiqGG25ZDP048z7YLTZYT1YnLV34w5HX3ZY2xxT54ZxL-lhDCR-D1aPYevwVi_CoHu8cD2OA55fvqd7jJ1M22VYLEkK-Su--PjlZC-U7po2p-8CacQrrHEqzbgKN85iE4cxxb4v5ZiC7h-jB1732T25XY_R5_OzT_MLcvXh7eX8zRUxXPCRSKm7rvOW8rZqa0Y74NbwujKaCy2drIUFKpjgznEPjnKg0nIqK29aarWvjtHrg-96062cNWXUpHu1TmGl005FHdTfyhCWahG3Ssha1nVTDF7cGqT4bePyqFYhG9f3enBxkxXjTUVLRkwW9Pk_6HXcpPKDEyXrljNoWaHYgTIp5pycv3sMBTVlrg6Zq5K52meuJutnf45xd-RXyAWoDkAu0rBw6ffd_7H9CaMLtiU</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Major, Attila Louis</creator><creator>Dvořák, Vladimír</creator><creator>Schwarzová, Jana</creator><creator>Skřivánek, Aleš</creator><creator>Malík, Tomáš</creator><creator>Pluta, Marek</creator><creator>Mayboroda, Ivanna</creator><creator>Grandjean, Etienne Marc</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1459-2727</orcidid></search><sort><creationdate>20210201</creationdate><title>Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial</title><author>Major, Attila Louis ; Dvořák, Vladimír ; Schwarzová, Jana ; Skřivánek, Aleš ; Malík, Tomáš ; Pluta, Marek ; Mayboroda, Ivanna ; Grandjean, Etienne Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-88abbbfd14939521b04dc453ca47a8e857d017274ee4f0e14018d4183fc91daf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Intravaginal</topic><topic>Adult</topic><topic>Antioxidants - administration & dosage</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer therapies</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Cervical Intraepithelial Neoplasia - pathology</topic><topic>Cervical Intraepithelial Neoplasia - therapy</topic><topic>Citric Acid - administration & dosage</topic><topic>Clinical trials</topic><topic>Colposcopy</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - drug effects</topic><topic>Cytodiagnosis</topic><topic>Endocrinology</topic><topic>Female</topic><topic>General Gynecology</topic><topic>Genes, p16</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Ki-67 Antigen - drug effects</topic><topic>Medical equipment</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Oxidative stress</topic><topic>Papillomavirus Infections - therapy</topic><topic>Papillomavirus Infections - virology</topic><topic>Pregnancy</topic><topic>Silicon Dioxide - administration & dosage</topic><topic>Sodium Selenite - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Uterine Cervical Neoplasms - prevention & control</topic><topic>Vagina</topic><topic>Vaginal Creams, Foams, and Jellies</topic><topic>Vaginal Smears</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Major, Attila Louis</creatorcontrib><creatorcontrib>Dvořák, Vladimír</creatorcontrib><creatorcontrib>Schwarzová, Jana</creatorcontrib><creatorcontrib>Skřivánek, Aleš</creatorcontrib><creatorcontrib>Malík, Tomáš</creatorcontrib><creatorcontrib>Pluta, Marek</creatorcontrib><creatorcontrib>Mayboroda, Ivanna</creatorcontrib><creatorcontrib>Grandjean, Etienne Marc</creatorcontrib><collection>Springer Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Major, Attila Louis</au><au>Dvořák, Vladimír</au><au>Schwarzová, Jana</au><au>Skřivánek, Aleš</au><au>Malík, Tomáš</au><au>Pluta, Marek</au><au>Mayboroda, Ivanna</au><au>Grandjean, Etienne Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>303</volume><issue>2</issue><spage>501</spage><epage>511</epage><pages>501-511</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Purpose
The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was investigated.
Methods
216 women aged 25–60 years were randomized to either receive an intravaginal daily dose of SAM gel for three 28-day periods, or be followed-up without intervention. The primary endpoint was efficacy, defined as a combined histological and cytological regression. At baseline and after 3 months participants had: a guided biopsy including p16 immunohistochemical (IHC) staining, only if a lesion was visible at colposcopy; a cervical smear for cytology, high-risk human papillomavirus (hr-HPV) and a p16/Ki-67 test. At 6 months a further cytology and p16/Ki-67 test was performed.
Results
Regression of CIN lesions was observed in 78 out of 108 patients (72.2%) in the SAM gel arm and in 27 out of 108 patients (25.0%) in the control arm. Similarly, the change in the p16/Ki-67 cytological test status was significantly in favor of the treatment arm. The prevalence of hr-HPV decreased significantly (
p
< 0.001) in the treatment arm, from 87.0% to 39.8%, while it slightly increased in the control arm, from 78.7% to 83.3%. At 6 months the cytological regression in the treatment group and the highly significant effect on p16/Ki-67 was still present.
Conclusion
SAM vaginal gel enhances the regression of cervical lesions and clears hr-HPV and p16/Ki-67 in smears significantly, thus offering an active non-destructive management to prevent cervical cancer.
Trial registration number
ISRCTN11009040, date of registration: 10/12/2019;
https://doi.org/10.1186/ISRCTN11009040
; retrospectively registered.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33219482</pmid><doi>10.1007/s00404-020-05816-8</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1459-2727</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0932-0067 |
| ispartof | Archives of gynecology and obstetrics, 2021-02, Vol.303 (2), p.501-511 |
| issn | 0932-0067 1432-0711 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7858556 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Administration, Intravaginal Adult Antioxidants - administration & dosage Biomarkers, Tumor - analysis Cancer therapies Cellular biology Cervical cancer Cervical Intraepithelial Neoplasia - pathology Cervical Intraepithelial Neoplasia - therapy Citric Acid - administration & dosage Clinical trials Colposcopy Cyclin-Dependent Kinase Inhibitor p16 - drug effects Cytodiagnosis Endocrinology Female General Gynecology Genes, p16 Gynecology Human Genetics Human papillomavirus Humans Ki-67 Antigen - drug effects Medical equipment Medical screening Medicine Medicine & Public Health Middle Aged Obstetrics/Perinatology/Midwifery Oxidative stress Papillomavirus Infections - therapy Papillomavirus Infections - virology Pregnancy Silicon Dioxide - administration & dosage Sodium Selenite - administration & dosage Treatment Outcome Uterine Cervical Neoplasms - prevention & control Vagina Vaginal Creams, Foams, and Jellies Vaginal Smears Womens health |
| title | Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A04%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20an%20adsorbent%20and%20anti-oxidative%20vaginal%20gel%20on%20CIN1%20and%202,%20on%20high-risk%20HPV,%20and%20on%20p16/Ki-67:%20a%20randomized%20controlled%20trial&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Major,%20Attila%20Louis&rft.date=2021-02-01&rft.volume=303&rft.issue=2&rft.spage=501&rft.epage=511&rft.pages=501-511&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-020-05816-8&rft_dat=%3Cproquest_pubme%3E2485942092%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2485942092&rft_id=info:pmid/33219482&rfr_iscdi=true |